Last $64.17 USD
Change Today -0.22 / -0.34%
Volume 1.4M
VRTX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 5:20 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

vertex pharmaceuticals inc (VRTX) Snapshot

Open
$64.18
Previous Close
$64.39
Day High
$65.68
Day Low
$63.42
52 Week High
07/19/13 - $89.96
52 Week Low
04/18/13 - $51.96
Market Cap
15.2B
Average Volume 10 Days
1.9M
EPS TTM
$0.20
Shares Outstanding
236.1M
EX-Date
--
P/E TM
326.9x
Dividend
--
Dividend Yield
--
Current Stock Chart for VERTEX PHARMACEUTICALS INC (VRTX)

vertex pharmaceuticals inc (VRTX) Related Businessweek News

View More BusinessWeek News

vertex pharmaceuticals inc (VRTX) Details

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. It markets KALYDECO in the United States and European Union as a treatment for the patients with cystic fibrosis six years of age and older who have the G551D mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. The company also provides INCIVEK in the United States and Canada for the treatment of adults with genotype 1 hepatitis C virus infection, as well as markets telaprevir in other international markets. It also develops Ivacaftor in combination with CFTR corrector compounds, which is in Phase III development program; and evaluates VX-661, a second investigational CFTR corrector, in combination with ivacaftor, in Phase II clinical development. The company identifies and develops next-generation CFTR corrector compounds that evaluate in regimens combining ivacaftor with two CFTR corrector compounds. It is involved in various other research and early-stage development programs, including programs in the areas of oncology, multiple sclerosis, and other serious and rare diseases. Vertex Pharmaceuticals Incorporated has collaboration agreements with Janssen Pharmaceutica NV and Mitsubishi Tanabe Pharma Corporation. The company was founded in 1989 and is headquartered in Boston, Massachusetts.

1,800 Employees
Last Reported Date: 02/11/14
Founded in 1989

vertex pharmaceuticals inc (VRTX) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.0M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $583.0K
Chief Scientific Officer, Executive Vice Pres...
Total Annual Compensation: $619.8K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $553.8K
Chief Legal Officer and Executive Vice Presid...
Total Annual Compensation: $465.0K
Compensation as of Fiscal Year 2013.

vertex pharmaceuticals inc (VRTX) Key Developments

Vertex Pharmaceuticals Incorporated Presents at Barclays Capital 2014 Global Healthcare Conference, Mar-11-2014 08:00 AM

Vertex Pharmaceuticals Incorporated Presents at Barclays Capital 2014 Global Healthcare Conference, Mar-11-2014 08:00 AM. Venue: Loews Miami Beach Hotel, Miami, Florida, United States. Speakers: Stuart A. Arbuckle, Chief Commercial Officer and Executive Vice President.

U.S. Food and Drug Administration Approves Vertex Pharmaceuticals Incorporated's KALYDECO (ivacaftor) for Use in Eight Additional Mutations That Cause Cystic Fibrosis

Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for KALYDECO(TM) (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight additional mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO was first approved in January 2012 for people with CF ages 6 and older who have at least one copy of the G551D mutation. With the approval of the sNDA, KALYDECO is now approved for use in people with CF with the following nine mutations: G551D, G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P and G1349D. In the United States, approximately 150 people ages 6 and older have one of the additional eight mutations for which KALYDECO is now approved. CF is caused by defective or missing CFTR proteins that result from mutations in the CFTR gene. The defective function or absence of CFTR proteins in people with CF results in poor flow of salt and water into and out of the cell in a number of organs, including the lungs. Ivacaftor facilitates increased chloride transport by potentiating the channel-open probability (or gating) of the CFTR protein. The sNDA approval is based on previously announced data from a Phase 3, two-part, randomized, double-blind, placebo-controlled, cross-over study of 39 people with CF who had one of the following mutations: G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P, G1349D or G970R. The study showed statistically significant improvements in lung function (FEV) for people in the overall study population who received ivacaftor, and the safety profile was similar to prior Phase 3 studies in people with the G551D mutation. Based on data from four patients with the G970R mutation enrolled in the study, the efficacy of KALYDECO in patients with the G970R mutation could not be established to support approval in the U.S. Vertex estimates that approximately 10 people with CF have the G970R mutation worldwide, including two people in the United States. Data from the study noted above were also used to support regulatory submissions in Europe, Canada and Australia for approval of KALYDECO in additional people with CF ages 6 and older.

Vertex Pharmaceuticals Incorporated Presents at RBC Capital Markets 2014 Global Healthcare Conference, Feb-25-2014 01:35 PM

Vertex Pharmaceuticals Incorporated Presents at RBC Capital Markets 2014 Global Healthcare Conference, Feb-25-2014 01:35 PM. Venue: New York Palace Hotel, New York, New York, United States. Speakers: Ian F. Smith, Chief Financial Officer and Executive Vice President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRTX:US $64.17 USD -0.22

VRTX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alexion Pharmaceuticals Inc $149.80 USD +0.75
Alkermes PLC $44.12 USD -0.91
BioMarin Pharmaceutical Inc $60.89 USD -0.48
Jazz Pharmaceuticals Plc $136.16 USD +0.055
United Therapeutics Corp $96.20 USD -2.02
View Industry Companies
 

Industry Analysis

VRTX

Industry Average

Valuation VRTX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.3x
Price/Book 11.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.9x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERTEX PHARMACEUTICALS INC, please visit www.vrtx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.